PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of thijTexas Heart Institute JournalSee also Cardiovascular Diseases Journal in PMCSubscribeSubmissionsTHI Journal Website
 
Tex Heart Inst J. 1990; 17(3): 194–202.
PMCID: PMC324917

Systemic Antifungal Agents

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.5M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Stein DK, Sugar AM. Fungal infections in the immunocompromised host. Diagn Microbiol Infect Dis. 1989 Jul-Aug;12(4 Suppl):221S–228S. [PubMed]
  • LOURIA DB. Some aspects of the absorption, distribution, and excretion of amphotericin B in man. Antibiotic Med Clin Ther. 1958 May;5(5):295–301. [PubMed]
  • Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990 Mar-Apr;12(2):308–329. [PubMed]
  • Eisenberg RS, Oatway WH. Nebulization of amphotericin B. Am Rev Respir Dis. 1971 Feb;103(2):289–292. [PubMed]
  • Bindschadler DD, Bennett JE. A pharmacologic guide to the clinical use of amphotericin B. J Infect Dis. 1969 Oct;120(4):427–436. [PubMed]
  • Block ER, Bennett JE, Livoti LG, Klein WJ, Jr, MacGregor RR, Henderson L. Flucytosine and amphotericin B: hemodialysis effects on the plasma concentration and clearance. Studies in man. Ann Intern Med. 1974 May;80(5):613–617. [PubMed]
  • Morgan DJ, Ching MS, Raymond K, Bury RW, Mashford ML, Kong B, Sabto J, Gurr FW, Somogyi AA. Elimination of amphotericin B in impaired renal function. Clin Pharmacol Ther. 1983 Aug;34(2):248–253. [PubMed]
  • Pennington JE, Block ER, Reynolds HY. 5-fluorocytosine and amphotericin B in bronchial secretions. Antimicrob Agents Chemother. 1974 Sep;6(3):324–326. [PMC free article] [PubMed]
  • Ismail MA, Lerner SA. Disseminated blastomycosis in a pregnant woman: review of amphotericin B usage during pregnancy. Am Rev Respir Dis. 1982 Aug;126(2):350–353. [PubMed]
  • Daneshmend TK, Warnock DW. Clinical pharmacokinetics of systemic antifungal drugs. Clin Pharmacokinet. 1983 Jan-Feb;8(1):17–42. [PubMed]
  • BUTLER WT, BENNETT JE, ALLING DW, WERTLAKE PT, UTZ JP, HILL GJ., 2nd NEPHROTOXICITY OF AMPHOTERICIN B; EARLY AND LATE EFFECTS IN 81 PATIENTS. Ann Intern Med. 1964 Aug;61:175–187. [PubMed]
  • Branch RA. Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch Intern Med. 1988 Nov;148(11):2389–2394. [PubMed]
  • Medoff G, Dismukes WE, Meade RH, 3rd, Moses JM. A new therapeutic approach to Candida infections. A preliminary report. Arch Intern Med. 1972 Aug;130(2):241–245. [PubMed]
  • Hermans PE, Keys TF. Antifungal agents used for deep-seated mycotic infections. Mayo Clin Proc. 1983 Apr;58(4):223–231. [PubMed]
  • Kennedy MS, Deeg HJ, Siegel M, Crowley JJ, Storb R, Thomas ED. Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation. Transplantation. 1983 Mar;35(3):211–215. [PubMed]
  • Paladino JA, Crass RE. Amphotericin B and flucytosine in the treatment of candidal cystitis. Clin Pharm. 1982 Jul-Aug;1(4):349–352. [PubMed]
  • Stamm AM, Dismukes WE. Current therapy of pulmonary and disseminated fungal diseases. Chest. 1983 Jun;83(6):911–917. [PubMed]
  • Athar MA, Winner HI. The development of resistance by candida species to polyene antibiotics in vitro. J Med Microbiol. 1971 Nov;4(4):505–517. [PubMed]
  • Seidenfeld SM, Cooper BH, Smith JW, Luby JP, Mackowiak PA. Amphotericin B tolerance: a characteristic of Candida parapsilosis not shared by other Candida species. J Infect Dis. 1983 Jan;147(1):116–119. [PubMed]
  • Maksymiuk AW, Thongprasert S, Hopfer R, Luna M, Fainstein V, Bodey GP. Systemic candidiasis in cancer patients. Am J Med. 1984 Oct 30;77(4D):20–27. [PubMed]
  • Price MF, Gentry LO. Incidence and significance of candida antigen in low-risk and high-risk patient populations. Eur J Clin Microbiol. 1986 Aug;5(4):416–419. [PubMed]
  • Salaki JS, Louria DB, Chmel H. Fungal and yeast infections of the central nervous system. A clinical review. Medicine (Baltimore) 1984 Mar;63(2):108–132. [PubMed]
  • Dismukes WE, Cloud G, Gallis HA, Kerkering TM, Medoff G, Craven PC, Kaplowitz LG, Fisher JF, Gregg CR, Bowles CA, et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med. 1987 Aug 6;317(6):334–341. [PubMed]
  • Zuger A, Louie E, Holzman RS, Simberkoff MS, Rahal JJ. Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment. Ann Intern Med. 1986 Feb;104(2):234–240. [PubMed]
  • Odds FC. Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro. Antimicrob Agents Chemother. 1982 Nov;22(5):763–770. [PMC free article] [PubMed]
  • Polsky B, Depman MR, Gold JW, Galicich JH, Armstrong D. Intraventricular therapy of cryptococcal meningitis via a subcutaneous reservoir. Am J Med. 1986 Jul;81(1):24–28. [PubMed]
  • Smego RA, Jr, Perfect JR, Durack DT. Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis. Rev Infect Dis. 1984 Nov-Dec;6(6):791–801. [PubMed]
  • Levine J, Bernard DB, Idelson BA, Farnham H, Saunders C, Sugar AM. Fungal peritonitis complicating continuous ambulatory peritoneal dialysis: successful treatment with fluconazole, a new orally active antifungal agent. Am J Med. 1989 Jun;86(6 Pt 2):825–827. [PubMed]
  • Collette N, van der Auwera P, Lopez AP, Heymans C, Meunier F. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob Agents Chemother. 1989 Mar;33(3):362–368. [PMC free article] [PubMed]
  • Stern GA, Fetkenhour CL, O'Grady RB. Intravitreal amphotericin B treatment of Candida endophthamitis. Arch Ophthalmol. 1977 Jan;95(1):89–93. [PubMed]
  • O'Day DM, Head WS, Robinson RD, Stern WH, Freeman JM. Intraocular penetration of systemically administered antifungal agents. Curr Eye Res. 1985 Feb;4(2):131–134. [PubMed]
  • Bennet JE. Flucytosine. Ann Intern Med. 1977 Mar;86(3):319–321. [PubMed]
  • Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, Gallis H, Leonard J, Fields BT, Bradshaw M, Haywood H, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med. 1979 Jul 19;301(3):126–131. [PubMed]
  • Stamm AM, Diasio RB, Dismukes WE, Shadomy S, Cloud GA, Bowles CA, Karam GH, Espinel-Ingroff A. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med. 1987 Aug;83(2):236–242. [PubMed]
  • Lopez-Berestein G, Mehta R, Hopfer RL, Mills K, Kasi L, Mehta K, Fainstein V, Luna M, Hersh EM, Juliano R. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis. 1983 May;147(5):939–945. [PubMed]
  • Lopez-Berestein G, Fainstein V, Hopfer R, Mehta K, Sullivan MP, Keating M, Rosenblum MG, Mehta R, Luna M, Hersh EM, et al. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis. 1985 Apr;151(4):704–710. [PubMed]
  • Lopez-Berestein G, Bodey GP, Fainstein V, Keating M, Frankel LS, Zeluff B, Gentry L, Mehta K. Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med. 1989 Nov;149(11):2533–2536. [PubMed]
  • Van Tyle JH. Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use. Pharmacotherapy. 1984 Nov-Dec;4(6):343–373. [PubMed]
  • Graybill JR. New antifungal agents. Eur J Clin Microbiol Infect Dis. 1989 May;8(5):402–412. [PubMed]
  • Johnson RJ, Blair AD, Ahmad S. Ketoconazole kinetics in chronic peritoneal dialysis. Clin Pharmacol Ther. 1985 Mar;37(3):325–329. [PubMed]
  • Duarte PA, Chow CC, Simmons F, Ruskin J. Fatal hepatitis associated with ketoconazole therapy. Arch Intern Med. 1984 May;144(5):1069–1070. [PubMed]
  • Sugar AM, Alsip SG, Galgiani JN, Graybill JR, Dismukes WE, Cloud GA, Craven PC, Stevens DA. Pharmacology and toxicity of high-dose ketoconazole. Antimicrob Agents Chemother. 1987 Dec;31(12):1874–1878. [PMC free article] [PubMed]
  • Schaffner A, Frick PG. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. J Infect Dis. 1985 May;151(5):902–910. [PubMed]
  • Craven PC, Graybill JR, Jorgensen JH, Dismukes WE, Levine BE. High-dose ketoconazole for treatment of fungal infections of the central nervous system. Ann Intern Med. 1983 Feb;98(2):160–167. [PubMed]
  • Lechi A, Montesi G, Dean P, Pancera P, Arosio E. Ketoconazole: clinical evaluation in severe fungal infections. Chemioterapia. 1986 Feb;5(1):18–22. [PubMed]
  • Barnert J, Behr W, Reich H. An amphotericin B-resistant case of rhinocerebral mucor mycosis. Infection. 1985 May-Jun;13(3):134–136. [PubMed]
  • Fainstein V, Bodey GP, Elting L, Maksymiuk A, Keating M, McCredie KB. Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients. Antimicrob Agents Chemother. 1987 Jan;31(1):11–15. [PMC free article] [PubMed]
  • Meunier-Carpentier F. Symposium on infectious complications of neoplastic disease (Part II). Chemoprophylaxis of fungal infections. Am J Med. 1984 Apr;76(4):652–656. [PubMed]
  • Perfect JR, Durack DT. Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. J Antimicrob Chemother. 1985 Jul;16(1):81–86. [PubMed]
  • Graybill JR. Systemic fungal infections: diagnosis and treatment. I. Therapeutic agents. Infect Dis Clin North Am. 1988 Dec;2(4):805–825. [PubMed]
  • Kwan JT, Foxall PJ, Davidson DG, Bending MR, Eisinger AJ. Interaction of cyclosporin and itraconazole. Lancet. 1987 Aug 1;2(8553):282–282. [PubMed]
  • Nováková I, Donnelly P, de Witte T, de Pauw B, Boezeman J, Veltman G. Itraconazole and cyclosporin nephrotoxicity. Lancet. 1987 Oct 17;2(8564):920–921. [PubMed]
  • Denning DW, Tucker RM, Hanson LH, Stevens DA. Treatment of invasive aspergillosis with itraconazole. Am J Med. 1989 Jun;86(6 Pt 2):791–800. [PubMed]
  • Faggian G, Livi U, Bortolotti U, Mazzucco A, Stellin G, Chiominto B, Vivani MA, Gallucci V. Itraconazole therapy for acute invasive pulmonary aspergillosis in heart transplantation. Transplant Proc. 1989 Feb;21(1 Pt 3):2506–2507. [PubMed]
  • De Beule K, De Doncker P, Cauwenbergh G, Koster M, Legendre R, Blatchford N, Daunas J, Chwetzoff E. The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study (1982-1987). Mycoses. 1988 Sep;31(9):476–485. [PubMed]
  • Elliott JA, Milne LJ, Cumming D. Chronic necrotising pulmonary aspergillosis treated with itraconazole. Thorax. 1989 Oct;44(10):820–821. [PMC free article] [PubMed]
  • Johnson PC, Khardori N, Najjar AF, Butt F, Mansell PW, Sarosi GA. Progressive disseminated histoplasmosis in patients with acquired immunodeficiency syndrome. Am J Med. 1988 Aug;85(2):152–158. [PubMed]
  • de Gans J, Eeftinck Schattenkerk JK, van Ketel RJ. Itraconazole as maintenance treatment for cryptococcal meningitis in the acquired immune deficiency syndrome. Br Med J (Clin Res Ed) 1988 Jan 30;296(6618):339–339. [PMC free article] [PubMed]
  • Denning DW, Tucker RM, Hanson LH, Hamilton JR, Stevens DA. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Intern Med. 1989 Oct;149(10):2301–2308. [PubMed]
  • Tucker RM, Denning DW, Dupont B, Stevens DA. Itraconazole therapy for chronic coccidioidal meningitis. Ann Intern Med. 1990 Jan 15;112(2):108–112. [PubMed]
  • Arndt CA, Walsh TJ, McCully CL, Balis FM, Pizzo PA, Poplack DG. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J Infect Dis. 1988 Jan;157(1):178–180. [PubMed]
  • Hay RJ. Overview of studies of fluconazole in oropharyngeal candidiasis. Rev Infect Dis. 1990 Mar-Apr;12 (Suppl 3):S334–S337. [PubMed]
  • Stern JJ, Hartman BJ, Sharkey P, Rowland V, Squires KE, Murray HW, Graybill JR. Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients. Am J Med. 1988 Oct;85(4):477–480. [PubMed]
  • Sugar AM, Saunders C. Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome. Am J Med. 1988 Oct;85(4):481–489. [PubMed]
  • Robinson PA, Knirsch AK, Joseph JA. Fluconazole for life-threatening fungal infections in patients who cannot be treated with conventional antifungal agents. Rev Infect Dis. 1990 Mar-Apr;12 (Suppl 3):S349–S363. [PubMed]
  • Cohen J. Treatment of systemic yeast infection with fluconazole. J Antimicrob Chemother. 1989 Feb;23(2):294–295. [PubMed]
  • Conti DJ, Tolkoff-Rubin NE, Baker GP, Jr, Doran M, Cosimi AB, Delmonico F, Auchincloss H, Jr, Russell PS, Rubin RH. Successful treatment of invasive fungal infection with fluconazole in organ transplant recipients. Transplantation. 1989 Oct;48(4):692–695. [PubMed]
  • Lee JW, Lin C, Loebenberg D, Rubin M, Pizzo PA, Walsh TJ. Pharmacokinetics and tissue penetration of Sch 39304 in granulocytopenic and nongranulocytopenic rabbits. Antimicrob Agents Chemother. 1989 Nov;33(11):1932–1935. [PMC free article] [PubMed]
  • Meunier F, Lambert C, Van der Auwera P. In-vitro activity of SCH39304 in comparison with amphotericin B and fluconazole. J Antimicrob Chemother. 1990 Feb;25(2):227–236. [PubMed]
  • Christiansen KJ, Bernard EM, Gold JW, Armstrong D. Distribution and activity of amphotericin B in humans. J Infect Dis. 1985 Nov;152(5):1037–1043. [PubMed]

Articles from Texas Heart Institute Journal are provided here courtesy of Texas Heart Institute